BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24722181)

  • 1. Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks.
    Nomiya T; Tsuji H; Maruyama K; Toyama S; Suzuki H; Akakura K; Shimazaki J; Nemoto K; Kamada T; Tsujii H;
    Br J Cancer; 2014 May; 110(10):2389-95. PubMed ID: 24722181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.
    Sato H; Kasuya G; Ishikawa H; Nomoto A; Ono T; Nakajima M; Isozaki Y; Yamamoto N; Iwai Y; Nemoto K; Ichikawa T; Tsuji H;
    Cancer Sci; 2021 Sep; 112(9):3598-3606. PubMed ID: 34107139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study.
    D'Agostino GR; Mancosu P; Di Brina L; Franzese C; Pasini L; Iftode C; Comito T; De Rose F; Guazzoni GF; Scorsetti M
    Am J Clin Oncol; 2020 Sep; 43(9):628-635. PubMed ID: 32889832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma.
    Byun HK; Kim C; Seong J
    Clin Mol Hepatol; 2023 Oct; 29(4):945-957. PubMed ID: 37583055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Who Will Benefit from Charged-Particle Therapy?
    Kim KS; Wu HG
    Cancer Res Treat; 2021 Jul; 53(3):621-634. PubMed ID: 34176253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolic repression effect of carbon-ion radiotherapy in synchronous hormone-sensitive oligometastatic prostate cancer.
    Zhang Z; Pei Y; Hu W; Xue Y; Ning R; Guo X; Sun Y; Zhang Q
    Front Endocrinol (Lausanne); 2023; 14():1291653. PubMed ID: 38027094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS).
    Nomiya T; Tsuji H; Kawamura H; Ohno T; Toyama S; Shioyama Y; Nakayama Y; Nemoto K; Tsujii H; Kamada T
    Radiother Oncol; 2016 Nov; 121(2):288-293. PubMed ID: 27836119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particle therapy for prostate cancer: The past, present and future.
    Ishikawa H; Tsuji H; Murayama S; Sugimoto M; Shinohara N; Maruyama S; Murakami M; Shirato H; Sakurai H
    Int J Urol; 2019 Oct; 26(10):971-979. PubMed ID: 31284326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbon Ion Radiation Therapy for Nonmetastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis.
    Miyasaka Y; Kawamura H; Sato H; Kubo N; Katoh H; Ishikawa H; Matsui H; Miyazawa Y; Ito K; Suzuki K; Ohno T
    Adv Radiat Oncol; 2024 Apr; 9(4):101432. PubMed ID: 38778824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year clinical outcomes of scanning carbon-ion radiotherapy for prostate cancer.
    Takakusagi Y; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Kamada T; Katoh H
    PLoS One; 2024; 19(3):e0290617. PubMed ID: 38457424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic and translational research on carbon-ion radiobiology.
    Sai S; Koto M; Yamada S
    Am J Cancer Res; 2023; 13(1):1-24. PubMed ID: 36777517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer.
    Hiroshima Y; Ishikawa H; Iwai Y; Wakatsuki M; Utsumi T; Suzuki H; Akakura K; Harada M; Sakurai H; Ichikawa T; Tsuji H
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical relative biological effectiveness and prostate-specific antigen kinetics of carbon-ion radiotherapy in low-risk prostate cancer.
    Kang YM; Ishikawa H; Inaniwa T; Iwai Y; Matsufuji N; Kasuya G; Okonogi N; Liu YM; Chao Y; Wakatsuki M; Tsujii H; Tsuji H
    Cancer Med; 2023 Jan; 12(2):1540-1551. PubMed ID: 35852142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbon-ion radiotherapy for urological cancers.
    Ishikawa H; Hiroshima Y; Kanematsu N; Inaniwa T; Shirai T; Imai R; Suzuki H; Akakura K; Wakatsuki M; Ichikawa T; Tsuji H
    Int J Urol; 2022 Oct; 29(10):1109-1119. PubMed ID: 35692124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced Radionuclides and Their Activity Concentration in Gel Dosimeters Irradiated by Carbon Ion Beam.
    Toyohara M; Minohara S; Kusano Y; Gotoh H; Tanaka Y; Yuhara M; Yamashita Y; Shimono Y
    Gels; 2022 Mar; 8(4):. PubMed ID: 35448104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flourish of Proton and Carbon Ion Radiotherapy in China.
    Li Y; Li X; Yang J; Wang S; Tang M; Xia J; Gao Y
    Front Oncol; 2022; 12():819905. PubMed ID: 35237518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300.
    Marvaso G; Vischioni B; Pepa M; Zaffaroni M; Volpe S; Patti F; Bellerba F; Gandini S; Comi S; Corrao G; Zerini D; Augugliaro M; Fodor C; Russo S; Molinelli S; Ciocca M; Ricotti R; Valvo F; Giandini T; Avuzzi B; Valdagni R; De Cobelli O; Cattani F; Orlandi E; Jereczek-Fossa BA; Orecchia R
    Front Oncol; 2021; 11():778729. PubMed ID: 34869026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Landscape of Carbon Ion Radiotherapy in Prostate Cancer: Clinical Application and Translational Research.
    Chen X; Yu Q; Li P; Fu S
    Front Oncol; 2021; 11():760752. PubMed ID: 34804961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Efficacy and Safety of Proton and Carbon Ion Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Li M; Li X; Yao L; Han X; Yan W; Liu Y; Fu Y; Wang Y; Huang M; Zhang Q; Wang X; Yang K
    Front Oncol; 2021; 11():709530. PubMed ID: 34712607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric Impact of Inter-Fraction Anatomical Changes in Carbon Ion Boost Treatment for High-Risk Prostate Cancer (AIRC IG 14300).
    Russo S; Ricotti R; Molinelli S; Patti F; Barcellini A; Mastella E; Pella A; Paganelli C; Marvaso G; Pepa M; Comi S; Zaffaroni M; Avuzzi B; Giandini T; Pignoli E; Valdagni R; Baroni G; Cattani F; Ciocca M; Jereczek-Fossa BA; Orlandi E; Orecchia R; Vischioni B
    Front Oncol; 2021; 11():740661. PubMed ID: 34650922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.